ESMO 2022 Conference Coverage
ESMO 2022 on the Randomized Phase 3 FORWARD I Study: Analyses of Patient-Reported Outcomes With Mirvetuximab Soravtansine vs. Standard Chemo in Ovarian Cancer
By
ESMO 2022 Conference Coverage
FEATURING
Kathleen Moore
By
ESMO 2022 Conference Coverage
FEATURING
Kathleen Moore
Comments 0
Login to view comments.
Click here to Login
